{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:50:47Z","timestamp":1789854647607,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jash.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T06:01:50Z","timestamp":1452492110000},"page":"271-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis"],"prefix":"10.1016","volume":"10","author":[{"given":"Genjiro","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2016.01.009_bib1","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2016.01.009_bib2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2013.451","article-title":"Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?","volume":"86","author":"Gilbert","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2016.01.009_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jash.2016.01.009_bib4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfu299","article-title":"Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease","volume":"30","author":"Vlotides","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jash.2016.01.009_bib5","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2016.01.009_bib6","series-title":"Kidney physiology and kidney disease","first-page":"17","author":"Maude","year":"1977"},{"key":"10.1016\/j.jash.2016.01.009_bib7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ki.1987.39","article-title":"The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism","volume":"31","author":"Greger","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2016.01.009_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jash.2016.01.009_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ki.1989.211","article-title":"Na+:K+:2Cl- cotransport and the thick ascending limb","volume":"36","author":"Molony","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2016.01.009_bib10","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/ki.1997.443","article-title":"Renal magnesium handling: new insights in understanding old problems","volume":"52","author":"Quamme","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2016.01.009_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jash.2016.01.009_bib12","series-title":"Hypertension: pathophysiology, diagnosis and management","first-page":"1569","article-title":"The renal basis for salt sensitivity in hypertension","author":"Kimura","year":"1995"},{"key":"10.1016\/j.jash.2016.01.009_bib13","series-title":"Hypertension primer","first-page":"488","article-title":"Treatment of diabetes and hypertension","author":"McFarlane","year":"2003"},{"key":"10.1016\/j.jash.2016.01.009_bib14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.HYP.35.4.864","article-title":"Association of insulin resistance with salt sensitivity and nocturnal fall\u00a0of blood pressure","volume":"35","author":"Suzuki","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.01.009_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)","volume":"37","author":"Shimamoto","year":"2014","journal-title":"Hypertens Res"},{"issue":"Suppl 1","key":"10.1016\/j.jash.2016.01.009_bib16","first-page":"S14","article-title":"Standards of medical care in diabetes\u20132014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2016.01.009_bib17","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/01.CIR.100.15.1635","article-title":"Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension","volume":"100","author":"Uzu","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2016.01.009_bib18","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/01.CIR.96.6.1859","article-title":"Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension","volume":"96","author":"Uzu","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2016.01.009_bib19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/HYPERTENSIONAHA.108.110213","article-title":"Kidney and circadian blood pressure rhythm","volume":"51","author":"Kimura","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.01.009_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/hr.2010.47","article-title":"Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events","volume":"33","author":"Kimura","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2016.01.009_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/01.HYP.27.4.914","article-title":"Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship","volume":"27","author":"Saito","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.01.009_bib22","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00004872-199612000-00013","article-title":"High sodium sensitivity and glomerular hypertension\/hyperfiltration in primary aldosteronism","volume":"14","author":"Kimura","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2016.01.009_bib23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1291\/hypres.29.645","article-title":"Pathophysiology of antihypertensive therapy with diuretics","volume":"29","author":"Fukuda","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2016.01.009_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jash.2016.01.009_bib25","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","article-title":"Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study","volume":"22","author":"Marre","year":"2004","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jash.2016.01.009_bib26","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2008.102","article-title":"Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study","volume":"73","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2016.01.009_bib27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jash.2016.01.009_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jash.2016.01.009_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11906-015-0551-3","article-title":"Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?","volume":"17","author":"Lovshin","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jash.2016.01.009_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jash.2016.01.009_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jash.2016.01.009_bib32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.01.009_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/01.HYP.35.5.1025","article-title":"Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program","volume":"35","author":"Franse","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.01.009_bib34","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1185\/03007995.2014.919907","article-title":"Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)","volume":"30","author":"Weir","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jash.2016.01.009_bib35","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jash.2016.01.009_bib36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2016.01.009_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bone.2015.04.026","article-title":"Effects of diabetes drugs on the skeleton","volume":"82","author":"Meier","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.jash.2016.01.009_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jash.2016.01.009_bib39","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2016.01.009_bib40","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2016.01.009_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1681\/ASN.V1191","article-title":"Effects of diuretic treatment and of dietary sodium on renal binding of 3H-metolazone","volume":"1","author":"Chen","year":"1990","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jash.2016.01.009_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1172\/JCI113847","article-title":"Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion","volume":"83","author":"Ellison","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jash.2016.01.009_bib43","first-page":"581","article-title":"Diuretic resistance: physiology and therapeutics","volume":"19","author":"Ellison","year":"1999","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jash.2016.01.009_bib44","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.V1271335","article-title":"Loop diuretic infusion increases thiazide-sensitive Na(+)\/Cl(\u2212)-cotransporter abundance: role of aldosterone","volume":"12","author":"Abdallah","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jash.2016.01.009_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jash.2016.01.009_bib46","first-page":"353","article-title":"Diabetes mellitus: a \u201cthrifty\u201d genotype rendered detrimental by \u201cprogress\u201d?","volume":"14","author":"Neel","year":"1962","journal-title":"Am J Hum Genet"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T08:22:56Z","timestamp":1654071776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171116000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1933171116000103"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2016.01.009","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}